<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669524</url>
  </required_header>
  <id_info>
    <org_study_id>H-15007312</org_study_id>
    <nct_id>NCT02669524</nct_id>
  </id_info>
  <brief_title>Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes</brief_title>
  <official_title>Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes - the Role of Glucagon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with type 2 diabetes, the incretin effect is markedly reduced contributing to the
      relative insulin deficiency that characterizes these patients. This defect is believed to be
      due to a decreased effect of GLP-1 and an almost ceased effect of GIP. Nevertheless, the
      impact of the defect on glucose tolerance is not fully understood. The so-called
      gastrointestinal-mediated glucose disposal (GIGD) is a measure of glucose handling, which
      includes the incretin effect, but also other factors affecting glucose disposal (e.g.
      glucagon secretion). Interestingly, patients with type 2 diabetes exhibit elevated plasma
      glucagon levels in the fasting state, and glucagon concentrations fail to decrease
      appropriately and may even increase in response to ingestion of glucose and show exaggerated
      increases after a mixed meal. With the current project the investigators wish to elucidate
      how this paradoxical glucagon response observed in patients with type 2 diabetes affects the
      GIGD, the incretin effect and postprandial glucose excursions.

      Ten patients with type 2 diabetes and 10 healthy matched control subjects will be enrolled in
      this randomised, placebo-controlled, double-blinded study. The aim is to examine the effect
      of a glucagon receptor antagonist (GRA) on gastrointestinal-mediated glucose disposal (GIGD),
      incretin effect and postprandial glucose excursions in patients with type 2 diabetes and
      healthy controls. Participants will attend two oral glucose tolerance tests (OGTT), two
      isoglycaemic iv glucose infusion (IIGI) and two standardised liquid meals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in GIGD (%)</measure>
    <time_frame>Comparison between experimental days with and without the glucagon receptor antagonist . The glucose disposal at time 240 minutes will be used.</time_frame>
    <description>GIGD = Gastrointestinal glucose disposal. GIGD (%) = 100% × (glucoseOGTT-glucoseIIGI)/glucoseOGTT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in postprandial glucose excursions</measure>
    <time_frame>Area under the curve (AUC) time frame: 0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 105, 120, 150, 180, 210, 240 minutes. Comparison between experimental days with and without the glucagon receptor antagonist.</time_frame>
    <description>Difference in postprandial glucose excursions (measured as incremental (baseline substracted) area under the curve (AUC) values).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incretin effect</measure>
    <time_frame>Insulin AUC time frame: 0,10, 20, 30, 50, 60, 70, 90, 105, 120, 150, 240 minutes. Comparison between experimental days with and without the glucagon receptor antagonist</time_frame>
    <description>The incretin effect (100% × [β-cell secretory response to oral glucose tolerance test − intravenous β-cell secretory response]/β-cell secretory response to oral glucose tolerance test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous glucose production</measure>
    <time_frame>Plasma concentration of 6,6^2 H2-glucose and U-13C^6-glucose at times: 0,10, 20, 30, 50, 60, 70, 90, 105, 120, 150, 240 minutes.</time_frame>
    <description>Glucose rate of appearance will be calculated by the non-steady state equation using double tracer technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipolysis</measure>
    <time_frame>Plasma concentration of 1,1,2,3,3-^2-H5 - glycerol measured at times: 0,10, 20, 30, 50, 60, 70, 90, 105, 120, 150, 240 minutes.</time_frame>
    <description>Glycerol disappearance will be calculated by the non-steady state equation using double tracer technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum/plasma concentrations of insulin, C-peptide, glucagon, GIP and GLP-1.</measure>
    <time_frame>Time frame: 0,10, 20, 30, 50, 60, 70, 90, 105, 120, 150, 240 minutes.</time_frame>
    <description>Insulin, C-peptide, glucagon, GIP and GLP-1 serum/plasma concentrations will be measured in pM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite</measure>
    <time_frame>VAS scales will be handed out at time 0, 30, 60, 90, 120, 150, 180 and 240 minutes.</time_frame>
    <description>Appetite will be evaluated with a visual analogue scale (VAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy intake (kcal/kJ)</measure>
    <time_frame>At time 240 to 270, the participants will eat an ad libitum meal. Comparison between experimental days with and without the glucagon receptor antagonist</time_frame>
    <description>At the end of the clamp experiment food intake will be examined with an ad libitum meal. The weight of the food will be measured i grams and calculated to the energy intake in kcal/kJ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure (mmHg)</measure>
    <time_frame>Measured at time 0 and time 210 minutes. Comparison between experimental days with and without the glucagon receptor antagonist</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pulse rate (beat per minute)</measure>
    <time_frame>Measured at time 0 and at time 210 minutes. Comparison between experimental days with and without the glucagon receptor antagonist</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in gastric emptying</measure>
    <time_frame>-30,-15, 0, 10, 20, 30, 50, 70, 90, 105, 120, 150, 240 minutes</time_frame>
    <description>Measurement of p-paracetamol. Measurement of time to peak and incremental area under the curve (iAUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free fatty acids</measure>
    <time_frame>-30,-15, 0, 10, 20, 30, 50, 70, 90, 105, 120, 150, 240 minutes</time_frame>
    <description>serum values of free fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroblast growth factor-21</measure>
    <time_frame>-30,-15, 0, 10, 20, 30, 50, 70, 90, 105, 120, 150, 240 minutes</time_frame>
    <description>plasma values of FGF-21</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>T2D + OGTT + LY2409021</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D + OGTT + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + placebo comparator to the human antagonist of the glucagon receptor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D + IIGI + LY2409021</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type 2 diabetes patients + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D + IIGI + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Type 2 diabetes patients + isoglycaemic iv glucose infusion + placebo comparator to the human antagonist of the glucagon receptor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D + MEAL + LY2409021</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type 2 diabetes patients + Standardised liquid meal + the human antagonist of the glucagon receptor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D + MEAL + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Type 2 diabetes patients + Standardised liquid meal + placebo comparator to the human antagonist of the glucagon receptor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTRL + OGTT + LY2409021</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTRL + OGTT + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy controls + 50 oral glucose tolerance test 4 hours + placebo comparator of the human antagonist of the glucagon receptor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTRL + IIGI + LY2409021</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTRL + IIGI + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy controls + isoglycaemic iv glucose infusion + placebo comparator the human antagonist of the glucagon receptor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTRL + MEAL + LY2409021</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls + Standardised liquid meal + the human antagonist of the glucagon receptor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTRL + MEAL + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy controls + Standardised liquid meal + placebo comparator of the human antagonist of the glucagon receptor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2409021</intervention_name>
    <arm_group_label>T2D + OGTT + LY2409021</arm_group_label>
    <arm_group_label>T2D + IIGI + LY2409021</arm_group_label>
    <arm_group_label>T2D + MEAL + LY2409021</arm_group_label>
    <arm_group_label>CTRL + OGTT + LY2409021</arm_group_label>
    <arm_group_label>CTRL + IIGI + LY2409021</arm_group_label>
    <arm_group_label>CTRL + MEAL + LY2409021</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2409021 placebo</intervention_name>
    <arm_group_label>T2D + OGTT + placebo</arm_group_label>
    <arm_group_label>T2D + IIGI + placebo</arm_group_label>
    <arm_group_label>T2D + MEAL + placebo</arm_group_label>
    <arm_group_label>CTRL + OGTT + placebo</arm_group_label>
    <arm_group_label>CTRL + IIGI + placebo</arm_group_label>
    <arm_group_label>CTRL + MEAL + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>OGTT</intervention_name>
    <arm_group_label>T2D + OGTT + LY2409021</arm_group_label>
    <arm_group_label>T2D + OGTT + placebo</arm_group_label>
    <arm_group_label>CTRL + OGTT + LY2409021</arm_group_label>
    <arm_group_label>CTRL + OGTT + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IIGI</intervention_name>
    <arm_group_label>T2D + IIGI + LY2409021</arm_group_label>
    <arm_group_label>T2D + IIGI + placebo</arm_group_label>
    <arm_group_label>CTRL + IIGI + LY2409021</arm_group_label>
    <arm_group_label>CTRL + IIGI + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standardised liquid meal</intervention_name>
    <arm_group_label>T2D + MEAL + LY2409021</arm_group_label>
    <arm_group_label>T2D + MEAL + placebo</arm_group_label>
    <arm_group_label>CTRL + MEAL + LY2409021</arm_group_label>
    <arm_group_label>CTRL + MEAL + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with type 2 diabetes

          -  Caucasians above 35 years of age with diet or metformin treated type 2 diabetes for at
             least 3 month (diagnosed according to the criteria of the World Health Organization
             (WHO)

          -  Normal haemoglobin

          -  Informed consent

        Healthy subjects

          -  Normal fasting plasma glucose (FPG) &lt;6.1 mmol/l and HbA1c &lt;42 mmol/mol (6.0%)

          -  Normal haemoglobin

          -  Age above 35 years

          -  Informed consent

        Exclusion Criteria:

        Patients with type 2 diabetes

          -  Inflammatory bowel disease

          -  Intestinal resections

          -  Nephropathy (serum creatinine above normal range and/or albuminuria)

          -  Liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate
             aminotransferase (ASAT) &gt;2×normal values)

          -  Treatment with medicine that cannot be paused for 12 hours

          -  Pregnancy and/or breastfeeding

          -  Family history of pancreatic islet tumours

          -  Age above 80 years

        Healthy subjects

          -  Diabetes or prediabetes with reduced glucose tolerance: FPG &gt;6.0 mmol/l and/or HbA1c
             &gt;42 mmol/mol

          -  First degree relatives with type 2 diabetes

          -  Inflammatory bowel disease

          -  Intestinal resections

          -  Treatment with medicine that cannot be paused for 12 hours

          -  Pregnancy and/or breastfeeding

          -  Age above 80 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center for Diabetes Research, Gentofte Hospital, Copenhagen University</name>
      <address>
        <city>Hellerup</city>
        <zip>DK-2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Sofie Hædersdal</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

